# Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling

> **NCT06298123** · — · COMPLETED · sponsor: **Chen Xiaoping** · enrollment: 304 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Adjuvant Immunotherapy
- Checkpoint Inhibitor

## Interventions

- **DRUG:** Anti-PD-1 monoclonal antibody

## Key facts

- **NCT ID:** NCT06298123
- **Lead sponsor:** Chen Xiaoping
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-01
- **Primary completion:** 2023-02-01
- **Final completion:** 2023-02-01
- **Target enrollment:** 304 (ACTUAL)
- **Last updated:** 2024-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06298123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06298123, "Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06298123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*